Open AccessEffects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
Author(s) -
Andrew McGarry,
Mika Lein,
Karl Kieburtz,
Michal Geva,
C. Warren Olanow,
Michael R. Hayden
Publication year - 2020
Publication title -
journal of huntington's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.081
H-Index - 24
eISSN - 1879-6400
pISSN - 1879-6397
DOI - 10.3233/jhd-200440
Subject(s) - placebo , repeated measures design , psychology , analysis of variance , population , medicine , post hoc analysis , physical therapy , statistics , mathematics , environmental health , pathology , alternative medicine
No pharmacological treatment has been demonstrated to provide a functional benefit for persons with Huntington's disease (HD). Pridopidine is a sigma-1-receptor agonist shown to have beneficial effects in preclinical models of HD.